Controlling Mers Of Coronavirus (Mers) And Preventing Its Further Spread
Coronavirus is a virus that causes a common childhood disease known as Colds. It tends to affect children between the ages of five and fourteen years. Children who are between the ages of five and fourteen years are most susceptible to the illness. Some children may experience flu-like symptoms before developing CoVs, but these symptoms often clear up within a week or two and do not result in death. A child who does not get CoV-2 could easily develop severe complications that require serious treatment.
A strain of this illness has been around for awhile and was last identified in China in 1984. It is thought that this strain originated in the poultry industry. The name for the virus is “Coxsack” after a man whose family emigrated to China. The name of the outbreak is “Crown-of-Fur.” In North America, the name of this illness is somewhat different, being known as “Cinderella.”
Symptoms for this disease tend to occur on their own without any obvious cause. Some children who contract CoV tend to have asthma when they are older. Other respiratory issues could cause cold like symptoms. The symptoms of coronavirus vary with each strain, making it possible for this virus to cause disease in a number of ways.
There are several vaccines available to protect against CoVs. These vaccines protect against strains associated with the Sars-Cov-2 virus. If an individual’s immune system is weakened by illness or other reasons, they may not be able to properly fight off the virus, resulting in infection. vaccinated individuals tend to have weaker immune systems than those who do not receive the vaccines. Additionally, children who receive these vaccinations remain at reduced risk of developing the illness in future years, but their immunity against the illness is lowered.
Another strain that is frequently associated with CoVs is “Thai-eye virus (end A)” or “HIV-1.” This virus has been identified in numerous outbreaks over the past ten years in Asia, causing a total deaths of more than twelve thousand people. There have been no deaths from a current outbreak in the United States or Canada. Unlike CoV, this strain does not have a vaccine.
In dealing with outbreaks of mers-cov virus, one of the key questions is what type of symptoms will be present. There have been several identified cases of a nasal discharge, fever, and loss of appetite, but these symptoms do not always reflect the full extent of a possible case. Conversely, most patients with mild respiratory illness may experience more severe symptoms such as cough, sneezing, and headache. Mers-Cov-2 is currently the only strain that is known to cause death from the disease; all others cause relatively minor, flu-like symptoms. Because of the varying symptoms, the virus is often confused with other diseases, resulting in misdiagnosis and consequently treatment.
A typical strategy for preventing the disease involves monitoring viral activity in the lab to determine when an outbreak is about to occur. If the lab measures show there is a high level of activity, a restriction level is implemented that will reduce the chance of an outbreak. Since the incubation period of mers-cov-2 is about two to three weeks, it is very difficult to identify when the disease will strike. Therefore, the Cleveland Clinic has developed an outbreak monitoring system using computerized surveillance software that allows disease representatives to prioritize contacts among patients. This system allows disease control staff to make quick decisions on where to focus resources and which contacts require special attention.
If you or someone you know contracts mers-cov-2, you should consider enrolling in a clinical trial of osprey blood disease. The drug administration arm of the Cleveland Clinic is conducting a clinical trial called the Trial for Recombinant DNA Medication, or TDRM. The goal of this trial is to find an exact dosage that will provide the highest levels of protection and provide proof that the disease can be controlled and eliminated. For more information on the trial, contact the Cleveland Clinic or visit their website.